# Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma

> **NCT00085189** · PHASE2 · COMPLETED · sponsor: **University of Southern California** · enrollment: 42 (actual)

## Conditions studied

- Ciliary Body and Choroid Melanoma, Medium/Large Size
- Ciliary Body and Choroid Melanoma, Small Size
- Extraocular Extension Melanoma
- Iris Melanoma
- Metastatic Intraocular Melanoma
- Mucosal Melanoma
- Recurrent Intraocular Melanoma
- Recurrent Melanoma
- Stage IIC Melanoma
- Stage IIIA Intraocular Melanoma
- Stage IIIA Melanoma
- Stage IIIB Intraocular Melanoma
- Stage IIIB Melanoma
- Stage IIIC Intraocular Melanoma
- Stage IIIC Melanoma
- Stage IV Intraocular Melanoma
- Stage IV Melanoma

## Interventions

- **BIOLOGICAL:** gp100 antigen
- **BIOLOGICAL:** tyrosinase peptide
- **BIOLOGICAL:** recombinant MAGE-3.1 antigen
- **BIOLOGICAL:** multi-epitope melanoma peptide vaccine
- **BIOLOGICAL:** incomplete Freund's adjuvant
- **DRUG:** Montanide ISA 51 VG
- **DRUG:** agatolimod sodium
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00085189
- **Lead sponsor:** University of Southern California
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-05
- **Primary completion:** 2007-09
- **Final completion:** 2007-09
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2014-05-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00085189

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00085189, "Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00085189. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*